Innovative early development regulatory approaches: expIND, expCTA, microdosing - PubMed (original) (raw)
Review
Innovative early development regulatory approaches: expIND, expCTA, microdosing
W T Robinson. Clin Pharmacol Ther. 2008 Feb.
Abstract
The Food and Drug Administration (FDA) Critical Path Initiative as well as the European Medicines Agency Road Map to 2010 (ref. 2) call for opportunities for more efficient drug development. One of the initiatives that has emerged in this context is the elaboration through guidance of exploratory investigational new drugs (INDs)/clinical trial applications (CTAs). This article reviews the history of these emerging guidances as well as the experience to date in their use by the industry.
Similar articles
- Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
Food and Drug Administration, HHS. Food and Drug Administration, HHS. Fed Regist. 2008 Jul 15;73(136):40453-63. Fed Regist. 2008. PMID: 18850678 - Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
Food and Drug Administration. HHS. Food and Drug Administration. HHS. Fed Regist. 2006 Jan 17;71(10):2458-62. Fed Regist. 2006. PMID: 16479693 - Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
Wang Y, Bhattaram AV, Jadhav PR, Lesko LJ, Madabushi R, Powell JR, Qiu W, Sun H, Yim DS, Zheng JJ, Gobburu JV. Wang Y, et al. J Clin Pharmacol. 2008 Feb;48(2):146-56. doi: 10.1177/0091270007311111. J Clin Pharmacol. 2008. PMID: 18199891 - Comparative requirements for exploratory clinical trials -- eIND, eCTA and microdosing.
Muller PY. Muller PY. Adv Drug Deliv Rev. 2011 Jun 19;63(7):511-7. doi: 10.1016/j.addr.2010.10.010. Epub 2010 Oct 26. Adv Drug Deliv Rev. 2011. PMID: 21034787 Review. - Innovative strategies for early clinical R&D.
Butz RF, Morelli G. Butz RF, et al. IDrugs. 2008 Jan;11(1):36-41. IDrugs. 2008. PMID: 18175261 Review.
Cited by
- The application of Phase 0 and microtracer approaches in early clinical development: past, present, and future.
Roffel AF, van Hoogdalem EJ. Roffel AF, et al. Front Pharmacol. 2024 Mar 18;15:1369079. doi: 10.3389/fphar.2024.1369079. eCollection 2024. Front Pharmacol. 2024. PMID: 38562464 Free PMC article. Review. - Healthy volunteers in first-in-human oncology drug development for small molecules.
de Las Heras B, Bouyoucef-Cherchalli D, Reeve L, Reichl A, Mandarino D, Flach S, Vidal L, van Brummelen EMJ, Steeghs N. de Las Heras B, et al. Br J Clin Pharmacol. 2022 Feb;88(4):1773-1784. doi: 10.1111/bcp.15092. Epub 2021 Oct 19. Br J Clin Pharmacol. 2022. PMID: 34558113 Free PMC article. Review. - Phase 0 Clinical Trial Strategies for the Neurosurgical Oncologist.
Sanai N. Sanai N. Neurosurgery. 2019 Dec 1;85(6):E967-E974. doi: 10.1093/neuros/nyz218. Neurosurgery. 2019. PMID: 31245813 Free PMC article. - HIV protease inhibitors in pulmonary hypertension: rationale and design of a pilot trial in idiopathic pulmonary arterial hypertension.
Li Y, Li XH, Yu ZX, Cai JJ, Billiar TR, Chen AF, Lv B, Chen ZY, Huang ZJ, Yang GP, Song J, Liu B, Yuan H. Li Y, et al. Pulm Circ. 2015 Sep;5(3):538-46. doi: 10.1086/682426. Pulm Circ. 2015. PMID: 26401255 Free PMC article. - Phase 0 clinical trials in oncology new drug development.
Gupta UC, Bhatia S, Garg A, Sharma A, Choudhary V. Gupta UC, et al. Perspect Clin Res. 2011 Jan;2(1):13-22. doi: 10.4103/2229-3485.76285. Perspect Clin Res. 2011. PMID: 21584177 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous